Navigation Links
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Date:6/1/2009

"As the leading cause of cancer deaths worldwide, lung cancer is a complex disease that requires new therapeutic options for patients," said Laura Brege, executive vice president and chief operating officer at Onyx Pharmaceuticals. "We are committed to studying Nexavar to understand how it may play a role in the treatment paradigm of this difficult-to-treat disease."

About Non-Small Cell Lung Cancer (NSCLC)

NSCLC accounts for 85-90 percent of diagnosed lung cancers(1) and is a disease in which malignant (cancer) cells form in the tissues of the lung. It is characterized by several types of lung cancers, each of which grow and spread in different ways, including: squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.(1)

Every year 1.4 million people worldwide will be diagnosed with lung cancer and 1.2 million will die from the disease.(2) Nearly 60 percent of Americans diagnosed with lung cancer die within one year of their diagnosis and 75 percent die within 2 years. These survival rates have not improved in the past 10 years.(3)

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 70 countries for liver cancer and in more than 80 countries for the treatment of patients with advanced kidney cancer. Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including, brea
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. IVCC launches groundbreaking insecticide projects with Bayer and Syngenta
2. AUDIO from Medialink and Bayer: Simple, Focused Ways to Boost Womens Health
3. Bayer HealthCare Cleared to Acquire Citracal(R)
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Bayer Foundation Grant Creates Graduate Engineering Fellowship at University of Houston
6. AUDIO from Medialink and Bayer: Is Your Pain Reliever Undermining Your Aspirin Therapy?
7. Bayer Temporarily Suspends Global Trasylol(R) Marketing
8. AUDIO from Medialink and Bayer: Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained with Naproxen Sodium
9. Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials
10. Bayer Awards Making Science Make Sense Grant to Girl Scouts
11. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... NY (PRWEB) May 24, 2013 The ... is happy to announce that it has donated $10,000 to ... the women held captive in Cleveland, Ohio. , “When the ... Jesus, Michelle Knight, and Amanda Berry and her daughter had ... a decade, we were shocked and horrified,” said Integrative Nutrition ...
(Date:5/24/2013)... more than half of recommended well-child visits had up ... who attended most of their visits, according to a ... Managed Care . The study included more than 20,000 ... with chronic conditions like asthma and heart disease were ... visits, according to the study. In fact, children ...
(Date:5/24/2013)... 2013 The Icahn School of Medicine ... exclusive license rights to commercially develop cardiomyocyte progenitors ... These cells are capable of further differentiation into the ... cells, and vascular smooth muscle cells, and thus could ... tissue. , The original agreement announced in May 2009 ...
(Date:5/24/2013)... -- Nearly three out of four pregnant women ... but these issues don,t significantly affect their quality ... from Loyola University Medical Center in Maywood, Ill., ... physiological and hormonal changes that occur during pregnancy. ... can play a role. The study authors added ...
(Date:5/24/2013)... May 24, 2013 Just about any bodyweight ... Mike Whitfield, a trainer based in Dallas, GA that uses ... there’s one pushup that is not used enough. , “The ... make the standard pushup more challenging. By keeping your hands ... and the abs are being worked much harder than a ...
Breaking Medicine News(10 mins):Health News:Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund 2Health News:Young children who miss well-child visits are more likely to be hospitalized 2Health News:Young children who miss well-child visits are more likely to be hospitalized 3Health News:Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles 2Health News:Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles 3Health News:Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles 4Health News:Bowel Issues Affect 3 Out of 4 Pregnant Women 2Health News:Medicine Ball Pushups, a Unique Bodyweight Chest Exercise, Released in Video from BodyweightTorch.com 2
... Thoracic Society has released a new official clinical policy ... pulmonary and critical care patients. The statement replaces ATS ... medications and treatment approaches, as well as provides an ... the January 1, 2011, issue of the American ...
... Eighth Annual Chronic Total Occlusion Summit and Left ... featuring state-of-the-art technologies, research findings and new developments ... optimize success in chronic total coronary occlusions and ... summit will include:, When and why to ...
... young women reach adulthood, their mothers can play a key ... vaccine, new research suggests. A study found that college-aged ... HPV vaccine if they had talked to their mother about ... factor in whether young women were vaccinated," said Janice Krieger, ...
... are a major complication in strabismus surgery. Amniotic membrane ... adhesions by forming a biological barrier during healing. In ... Journal of AAPOS , the Official Publication of ... team of researchers from Cairo University have discovered that ...
... (Boston) - Researchers from Boston University School of Medicine ... risk-adjusted percent time in therapeutic range (TTR) should be ... control and thus improve patient outcomes. These findings appear ... and Outcomes . Oral anticoagulation with warfarin is ...
... The pen may be mightier than the scale when it comes ... of snacks and meals is one of the best methods used ... management and diabetes specialist at Greenwich Hospital in Greenwich, Conn. ... you lose [weight] if you do it consistently," he said in ...
Cached Medicine News:Health News:ATS issues statement on the treatment of pulmonary fungal infections 2Health News:ATS issues statement on the treatment of pulmonary fungal infections 3Health News:ATS issues statement on the treatment of pulmonary fungal infections 4Health News:Mothers key to college-age women receiving HPV vaccine 2Health News:Use of amniotic membrane may cause complications in strabismus surgery 2Health News:Researchers measure quality of care in oral anticoagulation 2
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... medical technology company, today scheduled a conference call to ... fiscal year 2013, ended April 30, 2013. The call ... 30, 2013. The Company will report financial results for ... markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
Inquire...
Inquire...
... wall of the serum tube is specially ... activate the coagulation process. Serum / gel ... base of the tube; during centrifugation, this ... serum and the blood cells. In the ...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: